Friday, February 6, 2015

Top 10 Sliver Stocks To Buy Right Now

Last week we held the monthly joint web chat for subscribers of The Energy Strategist and MLP Profits. The chat is conducted by Igor Greenwald, managing editor for TES and chief investment strategist for MLP Profits, and myself.

There was a large spike in interest in the latest chat, and we received a larger than normal number of questions. We place a priority on answering questions about portfolio holdings and recommendations during the chat, but are often asked about other companies in the energy sector. Sometimes we may get questions that require an extended answer, or there may just be so many questions we can’t get to them all. I will address four remaining MLP questions from the chat below. (For answers to some remaining chat questions on energy companies outside the MLP space, see this week’s Energy Letter.)

Q: Would you put KYE in an IRA?

We got several questions about Kayne Anderson Energy Total Return Fund (NYSE: KYE) during the chat. The main advantage of closed-end MLP funds is the diversification they provide, along with the convenience of a 1099 miscellaneous income tax form instead of having to deal with K-1 forms from each individual MLP. This makes a closed-end MLP fund a more attractive option for an IRA.

Best Forestry Companies To Invest In 2015: Cell Therapeutics Inc (CTIC)

Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.

Pixuvri

As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.

OPAXIO

OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.

Tosedostat

In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.

Brostallicin

As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).

The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.

Advisors' Opinion:
  • [By MONEYMORNING]

    Cell Therapeutics Inc. (Nasdaq: CTIC), based in Seattle, Wash., acquires, develops, and commercializes treatments for cancers, including non-Hodgkin's leukemia and ovarian, neck, and brain cancers. The company just announced it has completed patient enrollment in clinical trials for an investigational agent to be used as a maintenance therapy in ovarian cancer patients. The trial is being conducted by the Gynecologic Oncology Group, one of the National Cancer Institute's funded research groups. Roth Capital recently reiterated a "Buy" rating on the stock and raised its price target from $6 to $7. Roth believes the company's treatment for leukemia, Pacritinib, is effectively evolving. Additionally, the investment firm sees potential in CTIC's Tosedostat, which deprives tumor cells of the amino acid building blocks needed to make proteins necessary for tumor cell survival. Shares rose 2% Tuesday to $3.52 on volume of 6 million shares.

  • [By Nathalie Tadena]

    Among the companies with shares expected to actively trade in Friday’s session are Vanda Pharmaceuticals Inc.(VNDA), Kimberly-Clark(KMB) and Cell Therapeutics(CTIC).

Top 10 Sliver Stocks To Buy Right Now: Acuity Brands Inc (AYI)

Acuity Brands, Inc. (Acuity Brands), incorporated on September 20, 2007, is the parent company of Acuity Brands Lighting, Inc. (ABL), and other subsidiaries. Acuity Brands is a provider of lighting solutions for commercial, institutional, industrial, infrastructure, and residential applications throughout North America and select international markets. The Company's lighting solutions include devices, such as luminaires, lighting controls, power supplies, prismatic skylights, light-emitting diode (LED) lamps, and integrated lighting systems for indoor and outdoor applications utilizing a combination of light sources, including daylight, and other devices controlled by software that monitors and manages light levels while optimizing energy consumption (collectively referred to herein as lighting solutions). Effective March 14, 2013, the Company acquired eldoLED Europe BV.

The Company manufactures lighting devices primarily in North America, Europe and Asia. The Company's lighting solutions are marketed under numerous brand names, including Lithonia Lighting, Holophane, Peerless, Mark Architectural Lighting, Hydrel, American Electric Lighting, Gotham, Carandini, RELOC, Antique Street Lamps, Tersen, Winona Lighting, Synergy Lighting Controls, Sensor Switch, Lighting Control & Design, Dark to Light, ROAM, Sunoptics, acculamp, Pathway Connectivity, and Healthcare Lighting. As of August 31, 2012, the Company manufactures products in 18 facilities in North America and two facilities in Europe.

Principal customers include electrical distributors, retail home improvement centers, electric utilities, municipalities, lighting showrooms, and energy service companies located in North America and select international markets serving new construction, renovation, and facility maintenance applications. In North America, the Company's lighting solutions are sold primarily by independent sales agents, electrical wholesalers, and factory sales representatives who cover specific geographic areas! and market channels. Products are delivered directly or through a network of distribution centers, regional warehouses, and commercial warehouses using both common carriers and a company-owned truck fleet. During the fiscal year ended August 31, 2012 (fiscal 2012), North American sales accounted for approximately 98% of net sales. The Company has one operating segment serving the North American lighting market and select international markets.

The Company provides a range of lighting solutions, as well as services used in the applications, such as lighting solutions and services. Lighting solutions and services includes commercial and institutional, industrial, infrastructure, residential and services. Commercial and Institutional includes stores, hotels, offices, schools, and hospitals, as well as other government and public buildings. Lighting solutions that serve these applications include recessed, surface, and suspended lighting products, recessed down lighting, track lighting, day lighting, and lighting controls (occupancy sensors, photocontrols, relay panels, architectural dimming panels, and integrated lighting controls systems), as well as special-use lighting products. The outdoor areas associated with these applications are addressed by a range of outdoor lighting products, such as area and flood lighting, decorative site lighting, and landscape lighting. Industrial includes primarily warehouses and manufacturing facilities, which utilize a range of general purpose, day lighting, and special-use lighting solutions. Infrastructure includes highways, tunnels, airports, railway yards, and ports. Products that serve these applications include street, area, high-mast, off-set roadway, sign lighting, poles, and integrated controls systems. Residential includes a combination of decorative, utilitarian, and down lighting products. Services include monitoring and controlling of lighting systems through network technologies.

The Company competes with Cooper Industries plc, Hu! bbell Inc! orporated, Koninklijke Philips Electronics N.V., OSRAM AG, Schneider Electric and General Electric Company.

Advisors' Opinion:
  • [By Monica Gerson]

    Acuity Brands (NYSE: AYI) is estimated to report its Q4 earnings at $$1.02 per share on revenue of $569.33 million.

    Walgreen Co (NYSE: WAG) is projected to report its Q4 earnings at $0.72 per share on revenue of $17.95 billion.

  • [By Rich Bieglmeier]

    [Related -Acuity Brands, Inc. (AYI) Q2 Earnings Preview: Red Lighting Earnings And Performance As Of Late]

    Liu Chun-ting, director general for Electronics and Optoelectronics Research Laboratories (EORL) under Taiwan government-sponsored Industrial Technology Research Institute (ITRI) projects a little stronger number, "Global LED lighting market value is estimated at US$30.5 billion for 2014 and will increase to US$51.6 billion in 2018."

  • [By Rich Duprey]

    Blinded by the light
    Philips will be introducing its new 200 lumen bulb in 2015 and expects that within 10 years half the world's fluorescents will be displaced. More importantly, their cost will fall rapidly with�their increased efficiency, making them cheaper to own within a year, as opposed to the current three years.�Acuity Brands� (NYSE: AYI  ) thinks Philips may still be in the dark about that, believing LEDs will surpass fluorescents in as little as three years' time.

Top 10 Sliver Stocks To Buy Right Now: British American Tobacco PLC (BATS)

British American Tobacco p.l.c. (British American Tobacco) is a holding company. The Company�� four principal brands include Dunhill, Kent, Lucky Strike and Pall Mall. The Company has many other famous international and local brands, including Rothmans, Vogue, Viceroy, Kool, Peter Stuyvesant and Benson & Hedges. The Company�� brands are sold in over 180 markets. The Company�� products include Cigarettes, Smokeless snus and Cigars. The Company has over 44 cigarette factories in 39 countries. In addition to cigarettes, the Company makes cigarillos, roll your own and pipe tobacco. Advisors' Opinion:
  • [By Namitha Jagadeesh]

    European stocks advanced for a fifth day, their longest rally this year, as data showed the U.K. avoided a triple-dip recession and as companies including British American Tobacco Plc (BATS) reported results.

Top 10 Sliver Stocks To Buy Right Now: TrueBlue Inc.(TBI)

TrueBlue, Inc. provides temporary blue-collar staffing services in the United States. It supplies on demand general labor to various industries under the Labor Ready brand; skilled labor to manufacturing and logistics industries under the Spartan Staffing brand; and trades people for commercial, industrial, and residential construction, and building and plant maintenance industries under the CLP Resources brand. The company also provides mechanics and technicians to the aviation maintenance, repair and overhaul, aerospace manufacturing, and assembly industries, as well as to other transportation industries under the Plane Techs brand; and temporary drivers to the transportation and distribution industries under the Centerline brand. It primarily serves small and medium-size businesses. The company was formerly known as Labor Ready, Inc. and changed its name to TrueBlue, Inc. in December 2007. TrueBlue, Inc. was founded in 1985 and is headquartered in Tacoma, Washington.

Advisors' Opinion:
  • [By Travis Hoium]

    What: Shares of staffing agency TrueBlue (NYSE: TBI  ) jumped 10% today after the company reported earnings.

    So what: Revenue jumped 19%, to $422.3 million, and beat estimates of $420.2 million from Wall Street. Adjusted earnings per share were also up 19%, to $0.31, outpacing estimates by $0.05.�

Top 10 Sliver Stocks To Buy Right Now: Indochine Mining Ltd (IDC)

Indochine Mining Limited is an Australia-based company developing and discovering gold and silver projects. The Company�� flagship asset is the Mt Kare gold-silver project in the highlands of Papua New Guinea (PNG). Mt Kare gold-silver project is held through its wholly owned PNG subsidiary, Summit Development Limited. The deposit lies 15 kilometers from the giant Porgera gold mine, which contains approximately 30 million ounces of gold. The Company holds two packages of exploration leases in Cambodia with potential for the discovery of gold and copper deposits. The Company�� projects in Cambodia include Kratie and Ratanakiri. Its subsidiaries include Indochine Resources Limited, Indochine Resources (Cambodia) Limited, Asia Pacific Gold & Copper Company Limited, Asia Pacific Gold & Copper (Cambodia) Limited, Aries Mining Limited, Summit Development Ltd and Positive Developments Limited. Advisors' Opinion:
  • [By Analyse360Degree]

    On Thursday, International Data Corporation (IDC) came out with its 2014 First Quarter Worldwide Quarterly Tablet Tracker and shed some light on the ongoing trends in the global tablet market. The figures reported by the data giant, though not very encouraging, were strong enough to bring smile on the faces of some tablet manufacturers, but Apple (AAPL), forcing us to think if this particular consumer electronic space is getting sour for the tech giant. Let�� take a look at what�� going on.

  • [By Bill Smith]

    FDS operates in a highly competitive industry, some with more resources. Their competitors include:
    Thomson Reuters Corp. (TRI)BloombergInteractive (IDC)MSCI Inc. (MXB)Morningstar Inc. (MORN)Track Data Corp. (TRAC)Edgar Online (EDGR)McGraw-Hill (MHP )

Top 10 Sliver Stocks To Buy Right Now: ForeverGreen Worldwide Corp (FVRG)

ForeverGreen Worldwide Corporation, incorporated on March 18, 1999, is a holding company that operates through its wholly owned subsidiary, ForeverGreen International, LLC. The Company's product philosophy is to develop, manufacture and market the science and nature through formulations as the Company produces and manufacture a wide arrays of whole foods, nutritional supplements, personal care products and essential oils. The Company provides health answers, not only through exclusive nutritional whole food beverages, but also by providing a broad product lines of delicious whole foods that can be eaten for every meal, instead of the processed, fatty and preservative-laden synthetic meals prevalent in society.

The Company provides the every-meal answer with a variety of appetizing healthy food products that allow its Members and customers to eat healthy for every meal and snack throughout the day. In addition, the Company provides healthy personal care products as an alternative to the chemical-laden and synthetic products in the marketplace that may potentially negatively impacts its health. The Company's products, along with a distinct and fresh corporate philosophy and message of physical, mental, emotional and spiritual health through service to community and others, attract consumers as well as Members who wish to own a home-based business selling the Company's products and spreading its health message.

The Company's primary product is FrequenSea, a whole-food beverage consisting of a blend of marine phytoplankton, ionic sea minerals, frankincense, rose, ginger and aloe vera in a base of blueberry, cranberry and lime juice concentrate. soluble. FrequenSea is sold as a single bottle, in individual single-serving packets or even in four-bottle packs. The marine phytoplankton in FrequenSea contains more than 200 different sea algae that are all processed through patent-pending harvesting processes. Azul is a rich-in-antioxidant, delicious powdered blend of 24 raw whole foo! d and fruit ingredients and probiotics that are naturally dried and blended to preserve their natural integrity.The Company's whole food offerings consist of a variety of healthy, natural food products that are made onsite in the Company's whole-food manufacturing facility. Versativa Pulse based with hemp seed, consists of 17 different nuts, seeds, fruits, grains and other whole foods. Pulse is offered in various flavors, either loose in bags or in snack bars, and may be used as a snack or a meal replacement.

The Company competes with NuSkin, Neways, Young Living Essential Oils, Amway Corporation, Herbalife and NuSkin Enterprises.

Advisors' Opinion:
  • [By CRWE]

    Last Friday, FVRG had shed (-15.38%) down -0.100 at $.550 with 20,050 shares in play at the close (ref. google finance August 16, 2013 ��Close).

    ForeverGreen Worldwide Corporation previously reported that sales are continuing to flourish. Sales for July 2013 increased to in excess of $1.44 million compared to $1.04 million during July 2012, an increase of 38.1%. Sequentially, sales increased 12.3% compared to June 2013.

  • [By CRWE]

    Today, FVRG remains (0.00%) +0.000 at $.780 thus far (ref. google finance Delayed: 10:06AM EDT August 12, 2013).

    ForeverGreen Worldwide Corporation previously reported that sales are continuing to flourish. Sales for July 2013 increased to in excess of $1.44 million compared to $1.04 million during July 2012, an increase of 38.1%. Sequentially, sales increased 12.3% compared to June 2013.

Top 10 Sliver Stocks To Buy Right Now: Harsco Corp (HSC)

Harsco Corporation, incorporated on February 28, 1956, is a diversified, multinational provider of industrial services and engineered products serving global industries. The Company operates in four segments: Harsco Metals & Minerals, Harsco Infrastructure, Harsco Rail and Harsco Industrial. The Company's principal lines of business include outsourced, on-site services to steel mills and other metals producers; resource recovery technologies for the re-use of industrial waste stream by-products; industrial abrasives and roofing granules; engineered scaffolding, concrete forming and shoring, and other access-related services, rentals and sales; railway track maintenance services and equipment; industrial grating products; air-cooled heat exchangers, and heat transfer products. In January 2014, the Company acquired Hammco Corp.

Harsco Metals & Minerals Segment

The Harsco Metals & Minerals Segment is a provider of on-site, outsourced services to the global metals industries. The Metals business provides its services and solutions on a long-term contract basis, supporting each stage of the metal-making process from initial raw material handling to post-production slag processing and metal recovery. The Minerals business extracts metallic content from stainless steel by-products and also specializes in the development of minerals technologies for commercial applications, including agriculture fertilizers. The Minerals business also produces industrial abrasives and roofing granules from power-plant utility coal slag at a number of locations throughout the United States. Harsco Minerals' BLACK BEAUTY abrasives are used for industrial surface preparation, such as rust removal and cleaning of bridges, ship hulls and various structures. Roofing granules are sold to residential roofing shingle manufacturers, primarily for the replacement roofing market. As of December 31, 2012, the Harsco Metals & Minerals Segment operated in approximately 35 countries. During the year ended December 3! 1, 2012, the Harsco Metals & Minerals Segment generated 46% of the Company�� total revenue.

Harsco Infrastructure Segment

The Harsco Infrastructure Segment is global organization for the rental and sale of engineered scaffolding, shoring, concrete forming and other access-related solutions for construction projects as well as industrial plant maintenance programs. The Segment operates from a network of branches throughout the world, including North America, Latin America, Europe, the Gulf Region of the Middle East, Africa and Asia-Pacific. The services include the provision of concrete shoring and forming systems; scaffolding for non-residential and infrastructure construction projects and industrial maintenance requirements, and a variety of other infrastructure services including project engineering and design, equipment erection and dismantling services, industrial insulation and painting services and equipment sales. During 2012, the Harsco Infrastructure Segment generated 31% of the Company�� total revenue.

Harsco Rail Segment

The Harsco Rail Segment is a global provider of equipment and services for the maintenance, repair and construction of railway track. The Segment's equipment and services support private and government-owned railroads and urban transit systems worldwide. The Segment's rail products are produced in three countries and products and services are provided worldwide. During 2012, the Harsco Rail Segment generated 11% of the Company�� total revenue.

Harsco Industrial Segment

Harsco Industrial Segment includes the Harsco Industrial IKG, Harsco Industrial Air-X-Changers and Harsco Industrial Patterson-Kelley businesses. Approximately 90% of this Segment's revenues originate in North America. Harsco Industrial IKG manufactures a line of industrial grating products at several plants in the United States and international plants located in Mexico and China. These products include a range of bar grating c! onfigurat! ions, which are used mainly in industrial flooring, as well as safety and security applications in the energy, paper, chemical, refining and processing industries.

Harsco Industrial Air-X-Changers is a supplier of custom-designed and manufactured air-cooled heat exchangers for the natural gas industry from plants in the United States and Australia. Harsco Industrial Air-X-Changers' heat exchangers are the primary apparatus used to condition natural gas during recovery, compression and transportation from underground reserves through the pipeline distribution channels. Harsco Industrial Patterson-Kelley is a manufacturer of heat transfer products, such as boilers and water heaters for commercial and institutional applications. During 2012, the Harsco Rail Segment generated 12% of the Company�� total revenue.

Advisors' Opinion:
  • [By Ben Levisohn]

    Shares of Harsco (HSC) have gained today after BB&T Capital Markets upgraded its shares to Buy from Hold.

    Analysts Robert Norfleet III and Basil Jones III explain the decision to raise their rating:

    �We believe that the strategic transformation of HSC’s portfolio, as evidenced by the recently announced sale of its Infrastructure segment, as well as additional best practices and productivity enhancements (LEAN, etc.) should result in improved financial metrics, valuation, and, ultimately, a less complex business structure. While our non-consensus call is not primarily based on an expedited improvement in financial performance, it is a reflection of our confidence in the new management team and its ability to deliver value to shareholders through asset repositioning, improved ROICs and free cash flow generation. HSC remains a “turnaround story,” but we believe the market is underestimating out-year earnings growth, which will be driven by the Brand Energy JV, lower corporate expenses, improved margins in Metals & Minerals and the likelihood of an accretive acquisition.

    Shares of Harsco have gained 4.7% to $26.43 today at 1:16 p.m., outpacing other construction & engineering companies. Dycom (DY) has advanced 0.5% to $30, KBR Inc. (KBR) has ticked up 0.1% to $33.03, Worthington Industries�(WOR) has risen 2.8% to $38.85�and Tutor Perini (TPC) has rallied 3.6% to $22.46.

No comments:

Post a Comment